A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV

NCT03755167 · clinicaltrials.gov ↗
PHASE2
Phase
SUSPENDED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped Study was suspended due to IPL344 shortage and may resume once drug supply is available. Survival follow-up is still ongoing following participants' consent

Conditions

Interventions

Sponsor

Immunity Pharma Ltd.